• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bayer A G Ord (OP:BAYZF)

    41.50 UNCHANGED
    Streaming Delayed Price Updated: 3:11 PM EDT, Jun 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 41.50
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 41.50
    Today's Range 41.50 - 41.50
    52wk Range 29.16 - 58.33
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
    From Bayer
    Via Business Wire
    News headline image
    Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
    From Bayer
    Via Business Wire

    Performance

    YTD
    -7.6%
    -7.6%
    1 Month
    -8.0%
    -8.0%
    3 Month
    -5.4%
    -5.4%
    6 Month
    +2.4%
    +2.4%
    1 Year
    +36.7%
    +36.7%

    More News

    Read More
    News headline image
    Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
    From Bayer
    Via Business Wire
    News headline image
    ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
    From Bayer
    Via Business Wire
    News headline image
    ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
    From Bayer
    Via Business Wire
    News headline image
    Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
    From Bayer
    Via Business Wire
    News headline image
    U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
    From Bayer
    Via Business Wire
    News headline image
    AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
    From Bayer
    Via Business Wire
    News headline image
    Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
    From Bayer
    Via Business Wire
    News headline image
    Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
    From Bayer
    Via Business Wire
    News headline image
    Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
    From Bayer
    Via Business Wire
    News headline image
    New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
    From Bayer
    Via Business Wire
    News headline image
    Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential
    From Bayer
    Via Business Wire
    News headline image
    Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
    From Bayer
    Via Business Wire
    News headline image
    KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
    From Bayer
    Via Business Wire
    News headline image
    New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
    From Bayer
    Via Business Wire
    News headline image
    Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
    From Bayer
    Via Business Wire
    News headline image
    Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
    From Bayer
    Via Business Wire
    News headline image
    Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
    From Bayer
    Via Business Wire
    News headline image
    Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
    From Bayer
    Via Business Wire

    Frequently Asked Questions

    Is Bayer A G Ord publicly traded?
    Yes, Bayer A G Ord is publicly traded.
    What exchange does Bayer A G Ord trade on?
    Bayer A G Ord trades on the OTC Traded
    What is the ticker symbol for Bayer A G Ord?
    The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded
    What is the current price of Bayer A G Ord?
    The current price of Bayer A G Ord is 41.50
    When was Bayer A G Ord last traded?
    The last trade of Bayer A G Ord was at 06/05/26 03:11 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.